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Background
Several recent studies have now firmly established a link
between the immune infiltrate in several human carci-
noma types and prognosis and/or response to therapy.
Correspondingly, increasing evidence suggests that the
number, type, and location of tumor-infiltrating lympho-
cytes in primary tumors harbor prognostic value, and
this has led to the development of a “tumor immuno-
score/immune index.”
Methods
The aim of this study was to develop Driver-Map™
ImmuneNet, a comprehensive cancer immuno-panel of
over one thousand genes to quantitatively assess the tran-
scriptome profile of the tumor microenvironment (e.g.
infiltrating immune cells, blood vessels, and stroma cells)
and allow accurate predictions of tumor purity. This
ImmuneNet panel includes approximately 400 immunity-
related genes from 16 predictive and prognostic core gene
signatures that have been validated in recent chemo- and
immunotherapy clinical trials across several tumor types,
including melanoma, colorectal, breast, and lung cancers.
In order to expand the core gene signatures, we developed
a non-probabilistic binary linear classifier algorithm to
infer the level of infiltrating immune cells in tumor tissues
using a novel multiplex Driver-Map pipeline. The Immu-
neNet panel also includes a comprehensive set of genes
specific for detection and quantitative profiling of different
types of activated immune cells of adaptive and innate
immunity, fibroblasts, stromal and endothelial cells in the
tumor microenvironment.
Results
Accordingly, the ImmuneNet panel allows quantitative
profiling of the expression levels of over 1000 key cancer
immuno-related genes using multiplex RT-PCR amplifi-
cation from 10-100ng of total RNA that is followed by
Next-Gen Sequencing. The built-in internal calibration
standards for each target gene allows calibration and
adjusting of digital NGS data depending on the level of
intrinsic noise and quality of samples. The ImmuneNet
panel is designed to be a robust platform with superior
sensitivity suitable for a variety of clinical samples. To
demonstrate the performance and utility of this panel, we
will present profiling data from infiltrating immune cells
and key intact and deficient immune mechanisms in the
tumor microenvironment of breast cancer samples. Com-
prehensive profiling of tumor-associated immune cells
with this gene panel will enable researchers to discover
prognostic and predictive immune response biomarkers,
to stratify cancer patients for responses to the growing
number of immunotherapeutic treatments.
Conclusions
ImmuneNet will not only enable large-scale analysis of
complex RNA mixtures for the discovery of novel cancer
biomarkers and therapeutic targets, it can be a useful plat-
form for exploring infiltrating cell types and obtaining
information of immune status.
Published: 4 November 2015
doi:10.1186/2051-1426-3-S2-P82
Cite this article as: Chenchik et al.: Cancer immunenet biomarker
profiling panel. Journal for ImmunoTherapy of Cancer 2015 3(Suppl 2):P82.
Cellecta, Inc., Mountain View, CA, USA
Chenchik et al. Journal for ImmunoTherapy of Cancer 2015, 3(Suppl 2):P82
http://www.immunotherapyofcancer.org/content/3/S2/P82
© 2015 Chenchik et al. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://
creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the
original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/
zero/1.0/) applies to the data made available in this article, unless otherwise stated.
